Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Two new meta-analyses found no clear increase in adverse maternal or fetal outcomes from GLP-1 receptor agonist use around conception or early pregnancy. However, researchers stress this isn't a green light — contraception is still strongly recommended during GLP-1 use, and the drugs should be stopped if pregnancy occurs. A first-ever international consensus statement now offers guidance for use before, during, and after pregnancy.
Two new systematic reviews and meta-analyses offer some reassurance about GLP-1 receptor agonist use around pregnancy, but researchers are careful not to overstate the findings. The first, published in Med, pooled data from over 2.1 million pregnancies and found no detectable increase in miscarriage, congenital anomalies, preterm birth, gestational diabetes, or other adverse outcomes among women exposed to GLP-1 drugs around conception. There was even a slightly lower rate of preeclampsia, though experts caution that finding needs more study.
The second meta-analysis, presented at the EASD annual meeting and published in Lancet Obstetrics, Gynaecology, & Women's Health, focused on over 40,000 women — mostly with type 2 diabetes — and similarly found no increased risk of congenital anomalies when GLP-1s were stopped in the first trimester. One flag: early pregnancy loss appeared more common in GLP-1-exposed women, though the authors noted this finding was difficult to interpret given that miscarriage and termination were combined in the largest contributing study.
Key Takeaways:
Why it matters: As GLP-1 drugs become increasingly popular, accidental exposure during early pregnancy is rising. These findings offer limited but meaningful reassurance — while reinforcing that current safety guidelines should stay in place until stronger evidence emerges.
